Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Drug

Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA

Fineline Cube Feb 8, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...

Company Deals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Fineline Cube Feb 8, 2025

Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...

Company Deals

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Fineline Cube Feb 7, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...

Company

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches

Fineline Cube Feb 7, 2025

China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...

Company

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products

Fineline Cube Feb 7, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...

Company Drug

CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA

Fineline Cube Feb 7, 2025

China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...

Company Drug

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS

Fineline Cube Feb 7, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...

Company Drug

Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease

Fineline Cube Feb 7, 2025

China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...

Company Drug

Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL

Fineline Cube Feb 7, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...

Company Drug

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study

Fineline Cube Feb 7, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...

Company Drug

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer

Fineline Cube Feb 7, 2025

Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...

Company Drug

Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease

Fineline Cube Feb 7, 2025

Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...

Company Drug

Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials

Fineline Cube Feb 7, 2025

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from...

Company Drug

Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials

Fineline Cube Feb 7, 2025

Beijing-based cell therapy developer Likang Life Sciences announced that it has received approval from the...

Company Deals

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition

Fineline Cube Feb 7, 2025

China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned...

Company Drug

EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment

Fineline Cube Feb 7, 2025

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer

Fineline Cube Feb 7, 2025

China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the global...

Company Drug

Bayer Files for EMA Approval of Kerendia for Heart Failure

Fineline Cube Feb 7, 2025

Bayer AG (FRA: BAYN) announced that it has made another market filing with the European...

Company

Boston Scientific Posts Strong Q4 and Full-Year 2024 Results

Fineline Cube Feb 7, 2025

Boston Scientific Corporation (NYSE: BSX) released its Q4 and full-year 2024 financial report, showing robust...

Company Deals

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange

Fineline Cube Feb 7, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to...

Posts pagination

1 … 210 211 212 … 659

Recent updates

  • Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
  • Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
  • Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem
  • Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform
  • Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Company Medical Device

Abbott Secures FDA Clearance and CE Mark for Ultreon 3.0 AI-Powered OCT Imaging Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.